Literature DB >> 32798017

GPR91 antagonist and TGF-β inhibitor suppressed collagen production of high glucose and succinate induced HSC activation.

Mutsuko Sakai1, Takaaki Sumiyoshi2, Takuma Aoyama3, Kenji Urayama3, Ryoichi Yoshimura4.   

Abstract

Activated hepatic stellate cells (HSCs) play a central role in fibrillary collagen production, the primary cause of liver fibrosis. Although it is known that primary cultured HSCs are activated by plastic culture dish stiffness, HSC activation and quiescent-state-reversion mechanisms are still unclear. In this study, we used cultured normal rat HSCs on 3.2 kPa collagen normal liver stiffness equivalent gel, to determine whether high glucose or high succinate conditions induce HSC activation, and examined whether activated HSCs reverted to a quiescent state when suppressed by GPR91 antagonists or TGF-β1 receptor inhibitors. We measured the gene expression levels of α-SMA and type I collagen HSC activation markers using real-time PCR. Our data indicated that high glucose conditions induced HSC activation, and showed that under continuous high glucose exposure HSC activation progressed. A GPR91 antagonist, 2 d, and a TGF-β1 receptor inhibitor, SB525334, suppressed the Col1α mRNA expression level of these activated HSCs. Similarly, under extended high succinate exposure, 2 d and SB525334 reduced Col1α mRNA expression levels of activated HSCs. From the above, we determined that even though HSCs had already been activated by high glucose or succinate conditions which persisted after activation, the GPR91 antagonist and the TGF-β1 receptor inhibitor were able to reduce the production of type I collagen from activated HSCs.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Collagen; GPR91; Hepatic stellate cells; High glucose; NAFLD/NASH; Succinate

Mesh:

Substances:

Year:  2020        PMID: 32798017     DOI: 10.1016/j.bbrc.2020.07.141

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates.

Authors:  Simon Ströbel; Radina Kostadinova; Katia Fiaschetti-Egli; Jana Rupp; Manuela Bieri; Agnieszka Pawlowska; Donna Busler; Thomas Hofstetter; Katarzyna Sanchez; Sue Grepper; Eva Thoma
Journal:  Sci Rep       Date:  2021-11-23       Impact factor: 4.379

2.  The angiotensin-converting enzyme inhibitor, captopril, suppressed hepatic stellate cell activation via NF-kappaB or wnt3α/β-catenin pathway.

Authors:  Zhaodi Gu; Linjun Fang; Peijun Ma
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.